A Phase 1 interventional study of TQB3909 tablets and TQB3702 tablets in Hematologic Malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.
Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 16th largest by planned enrollment of the 123 interventional ones that give a count, is one of 16 that started in 2024, is one of 57 in phase 1, reaches primary completion later than 22 of the 82 other live ones, and was the 94th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.
Browse Hematologic Neoplasms studies →75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Chinese PLA General Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
148 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 41 · Phase 3 15 · Phase 4 5
First in 2008; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 208 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 56 across the 123 interventional studies, 88 across the 24 observational. Of the 32 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 148 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 6 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Hematologic Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07014449Hangzhou Weben Pharma Co., LtdClinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | 2026-12 |
| NCT06066203Sichuan Baili Pharmaceutical Co., Ltd.A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
| NCT06225856Shanghai Yuyao Biotech Co., Ltd.An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | 2026-12-30 |
| NCT05255926Zhongnan HospitalCXCR4-targeted PET/CT Imaging in Hematological Malignancies | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 148 studies in Hematologic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the first phase. The purpose is to evaluate the safety and preliminary efficacy of TQB3909 tablets combined with TQB3702 tablets in hematologic malignancy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject population:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TQB3909 tablets combined with TQB3702 tablets, administered orally, 28 days as a treatment cycle.
Drug: TQB3909 tablets · Drug: TQB3702 tablets
TQB3909 is a protein inhibitor.
TQB3702 is a kinase inhibitor.
Dose limited toxicity (DLT)
DLT will be defined as toxicities that meet pre-defined severity criteria (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0), and assessed as having a suspected relationship to study drug.
Time frame: Baseline up to 104 weeks
Adverse events (AE)
The occurrence of all adverse events (AE).
Time frame: Baseline up to 104 weeks
Serious adverse events (SAE)
The occurrence of all serious adverse events (SAE).
Time frame: Baseline up to 104 weeks
Clinical laboratory abnormalities
Incidence of participants with abnormal clinical laboratory test results.
Time frame: Baseline up to 104 weeks
Complete remission rate (CRR)/ Complete remission with incomplete bone marrow recovery rate (CRi)
The proportion of patients with tumor hat have a complete response or complete remission with incomplete bone marrow recovery after treatment.
Time frame: Baseline up to 104 weeks
Objective Response Rate (ORR)
The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period.
Time frame: Baseline up to 104 weeks
Undetectable measurable residual disease (U-MRD) ratio of peripheral blood and/or bone marrow
Refers to the undetected residual lesions. Flow cytometry was used to detect less than 1 Chronic Lymphocytic Leukemia (CLL) cell (less than 10-4) in 10,000 white blood cells in peripheral blood and/or bone marrow.
Time frame: Baseline up to 104 weeks
Duration of complete remission / complete remission with incomplete bone marrow recovery
The time from the date of first achieving CR or CRi to the date of first definite disease progression or death from any cause (whichever occurs first).
Time frame: Baseline up to 104 weeks
Duration of Response (DOR)
For all subjects whose best response was partial response (PR), Complete Response (CR), the time from the date of first achieving PR, CR to the date of first definite disease progression or death from any cause (whichever occurs first).
Time frame: Baseline up to 104 weeks
Time to complete remission
The time from beginning the treatment to the first achieving complete remission/ complete remission with incomplete bone marrow recovery.
Time frame: Baseline up to 104 weeks
Time to remission (TTR)
Time from the beginning of treatment to the first recording of remission (PR or better remission), only the remission population will be analyzed.
Time frame: Baseline up to 104 weeks
Progression Free Survival (PFS)
The time from the first dose to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first
Time frame: Baseline up to 104 weeks
Overall Survival (OS)
The time from start of study treatment to date of death due to any cause.
Time frame: Baseline up to 104 weeks
2 years' PFS rate
The proportion of patients with progression free survival in 2 years.
Time frame: Baseline up to 104 weeks
2 years' OS rate
The proportion of patients achieving overall survival in two years.
Time frame: Baseline up to 104 weeks
Time to reach the maximum plasma concentration (Tmax)
Time to reach the maximum plasma concentration after dose
Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.
Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)
Cmax is the maximum plasma concentration of TQB3909 and TQB3702
Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.
Minimum steady-state plasma drug concentration during a dosage interval (Css-min)
Cmin is the minimum plasma concentration of TQB3909 and TQB3702.
Time frame: Before the first dose of TQB3702 tablet and target dose of TQB3909 tablet. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 hours after the first target dose of TQB3909 tablet. The 4th /11th day before dosing with target dose of TQB3909 tablet.
Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.
Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 23 months is below that.
Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bcl-2 Inhibitor TQB3909 · BTK Inhibitor TQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →